Background: The CFTR-Ser737 site has a phospho-dependent inhibitory effect on Cl− secretion.
Results: LMTK2 phosphorylation of CFTR-Ser737 facilitates endocytosis, reduces cell surface density of CFTR, and inhibits Cl− secretion.
Conclusion: Targeting LMTK2 regulates the cell surface density of CFTR Cl− channels.
Significance: Targeting LMTK2 in CF patients may stabilize ΔF508-CFTR pharmacologically rescued to the cell surface.
Keywords: CFTR, Chloride Transport, Cystic Fibrosis, Endocytosis, Epithelial Cell, Protein Phosphorylation
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl−-selective ion channel expressed in fluid-transporting epithelia. Lemur tyrosine kinase 2 (LMTK2) is a transmembrane protein with serine and threonine but not tyrosine kinase activity. Previous work identified CFTR as an in vitro substrate of LMTK2, suggesting a functional link. Here we demonstrate that LMTK2 co-immunoprecipitates with CFTR and phosphorylates CFTR-Ser737 in human airway epithelial cells. LMTK2 knockdown or expression of inactive LMTK2 kinase domain increases cell surface density of CFTR by attenuating its endocytosis in human airway epithelial cells. Moreover, LMTK2 knockdown increases Cl− secretion mediated by the wild-type and rescued ΔF508-CFTR. Compared with the wild-type CFTR, the phosphorylation-deficient mutant CFTR-S737A shows increased cell surface density and decreased endocytosis. These results demonstrate a novel mechanism of the phospho-dependent inhibitory effect of CFTR-Ser737 mediated by LMTK2 via endocytosis and inhibition of the cell surface density of CFTR Cl− channels. These data indicate that targeting LMTK2 may increase the cell surface density of CFTR Cl− channels and improve stability of pharmacologically rescued ΔF508-CFTR in patients with cystic fibrosis.
Introduction
The cystic fibrosis transmembrane conductance regulator (CFTR),3 a member of the ATP binding cassette (ABC) transporter superfamily functions as a cAMP-activated Cl−-selective ion channel in various fluid-transporting epithelia (1–3). CFTR is present in many tissues including the airway where it plays a critical role in regulating mucociliary clearance by maintaining the homeostasis of the airway surface liquid (4, 5). CFTR-mediated Cl− secretion across polarized epithelial cells is regulated by adjusting activity and density of the CFTR Cl− channels at the cell surface (6–10). The cell surface abundance of CFTR depends on its biosynthetic processing and post-maturational trafficking, a process of endocytic uptake followed either by recycling to the plasma membrane or trafficking for lysosomal degradation (reviewed in Ref. 11). Despite inefficient biosynthetic processing, CFTR abundance at the cell surface is maintained after rapid endocytosis via clathrin-dependent pathway because CFTR is efficiently recycled (12–15). Deletion of Phe-508 (ΔF508) resulting from the most common CFTR gene mutation in patients with cystic fibrosis (CF) leads to a biosynthetic processing defect of the CFTR protein (11). Pharmacological correction of the processing defect has been highly anticipated as a disease modifying therapy because rescue of the cell surface ΔF508-CFTR abundance partially restores the CFTR Cl− channel function (16). Several small molecules called CFTR correctors have been shown to rescue the cell surface expression of ΔF508-CFTR by improving its biosynthetic processing defect in cultured cells (16–19). Correction of the processing defect revealed that rescued (r)ΔF508-CFTR is only partially functional as a Cl− channel, in part because the mutation also alters the post-maturational trafficking and decreases the plasma membrane stability of rΔF508-CFTR (15, 20). The present generation of CFTR correctors does not improve the reduced plasma membrane stability of rΔF508-CFTR, and their clinical efficacy has been limited in patients homozygous for the ΔF508 mutation (16, 21). Hence, understanding regulation of the post-maturational trafficking of CFTR is critical to design effective treatments for CF. Although numerous adaptors have been shown to mediate the post-maturational trafficking of CFTR little is known how this process is regulated (7, 9, 10, 22–30).
The activity of CFTR as a Cl− channel is regulated by protein kinases including protein kinase PKA, PKC, and adenosine monophosphate-stimulated kinase (AMPK) (reviewed in Ref. 31). These kinases target sites in the regulatory domain of CFTR (32, 33). Two of the sites, Ser737 and Ser768 have a phospho-dependent inhibitory effect on the CFTR channel function (32). Phosphorylation of these inhibitory sites by AMPK inhibits CFTR-mediated Cl− secretion by maintaining the CFTR channels in a closed state (34, 35). Previous work demonstrated that the Ser737 site in the recombinant CFTR regulatory domain can be phosphorylated by purified lemur tyrosine kinase 2 (LMTK2) in vitro (36). Still, it is unknown whether CFTR is an LMTK2 substrate in airway epithelial cells.
LMTK2 also known as kinase/phosphatase/inhibitor-2 (KPI2), brain-enriched kinase (BREK), apoptosis-associated tyrosine kinase (AATYK2), and cyclin-dependent kinase-5 (cdk5/p35) regulated kinase, is a member of the lemur family of membrane-anchored kinases (37–41). Despite the original prediction to be a dual-specificity serine-threonine/tyrosine kinase, studies have shown that purified LMTK2 kinase domain phosphorylates only serine and threonine residues (36, 37, 39). The biological actions of LMTK2 are best described in neuronal and muscle tissues where it plays a role in intracellular trafficking (42–47). LMTK2 forms a regulatory complex with several cytosolic proteins (reviewed in Ref. 48). As shown schematically in Fig. 1A, the N-terminal transmembrane domain anchors LMTK2 at the plasma membrane and is followed by the kinase domain (37, 41). The residue Lys168 located upstream of the Walker A motif in the catalytic domain is critical for kinase activity (49, 50). The amino acid residues 567–773 mediate direct interaction with myosin VI (43), an actin-based minus-end directed non-conventional motor known to facilitate CFTR endocytosis (26). At the C terminus LMTK2 has a long tail domain that prompted naming the protein after the lemur, a long-tailed Madagascar primate (37). Some of the recognized LMTK2 effects may be cell-type and tissue specific. Thus far nothing is known about the role of LMTK2 in airway epithelial cells. The goals of this study were to determine the localization of LMTK2, whether it associates with and phosphorylates CFTR at residue Ser737 (CFTR-Ser737) and whether the LMTK2-mediated phosphorylation regulates CFTR endocytic trafficking in human airway epithelial cells. We demonstrate that phosphorylation of CFTR-Ser737 mediated by LMTK2 facilitates endocytosis and reduces the cell surface density of CFTR Cl− channels in human airway epithelial cells. Moreover, LMTK2 knockdown increases Cl− secretion mediated by the wild-type (WT) and rΔF508-CFTR. Thus, interfering with LMTK2 phosphorylation of ΔF508-CFTR-Ser737 may serve as a novel strategy to improve the cell surface stability of pharmacologically rescued ΔF508-CFTR in CF patients.
MATERIALS AND METHODS
Cell Lines and Cell Culture
Primary differentiated human bronchial epithelial (HBE) cells (WT-CFTR homozygous) were received from Dr. Joseph Pilewski (Cystic Fibrosis Research Center Epithelial Cell Core at the University of Pittsburgh School of Medicine, Pittsburgh, PA) (51–53). HBE cells were studied because they are considered a gold standard for CFTR research (54); however, these cells are not always available and cannot be passaged, so their use is severely limited. Cells were cultured on human placental collagen-coated Costar Transwell permeable supports (1.12 cm2 at a density ∼7 × 105/cm2 as previously described and used for experimentation following 6–8 weeks of culture at an air-liquid interface (53).
Human airway epithelial Calu-3 cells that express CFTR endogenously were obtained from the American Type Culture Collection (Manassas, VA). Cells were seeded on Transwell permeable supports (4.67 cm2 at density ∼1 × 106) coated with plating medium containing Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) and 10% purified collagen (PureColTM; Advanced Biomatrix, San Diego, CA) and used for experimentation following 3–4 weeks of culture at an air-liquid interface as described previously (27). Calu-3 cells were studied because they express high endogenous levels of CFTR and LMTK2; however, Calu-3 cells are very difficult to transfect.
Human bronchial epithelial cells CFBE41o- stably expressing either WT-CFTR or ΔF508-CFTR cells and parental CFBE41o- (no CFTR transduction), were a generous gift from Dr. J. P. Clancy from the Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH (15, 55). CFBE41o- cells were used because they are isogenic except for CFTR, and they are relatively easy to transfect. CFBE41o- cells express WT-CFTR and ΔF508-CFTR transgenes, thus, studies on these cells do not examine endogenous CFTR. However, stable expression of WT-CFTR in CFBE41o- cells is comparable to endogenous CFTR expression in Calu-3 and HBE cells (9, 26, 53), thus making it a good model of human airway epithelial cells to study regulated CFTR trafficking. CFBE41o- cells were seeded on Transwell permeable supports (4.67 cm2 at density ∼1 × 106) coated with plating medium and used for experimentation following 7–9 days of culture at an air-liquid interface as described previously (9, 10). CFBE41o- cells transfected with siRNA were seeded on collagen-coated plastic tissue culture plates (Corning Corporation) and cultured for 96 h to form monolayers. CFBE41o- cells transduced with shRNA were seeded on collagen-coated Snapwell or Transwell permeable supports (Corning Corporation) and cultured for 7–9 days to form polarized monolayers. CFBE41o- cells transfected with plasmid DNA were seeded on collagen-coated plastic tissue culture plates and cultured for 48 h to form monolayers. Fetal bovine serum (FBS) and the selection antibiotic were removed from the media 24 h before experiments to augment cell polarization and cell cycle synchronization (56, 57).
HEK293 cells from the American Type Culture Collection were transfected with plasmid DNA, seeded on plastic tissue culture plates, and used 24 h later for kinase assays. HEK293 cells were also used as a well-accepted model to express recombinant proteins and conduct biochemical studies including the kinase assay.
Antibodies and Reagents
The following anti-human CFTR antibodies were used: mouse monoclonal, clone 596 (Cystic Fibrosis Foundation Therapeutics, Inc.; Chapel Hill, NC) and clone M3A7 (Millipore; Billerica, MA), and rabbit polyclonal Ab-737 (Assay Biotechnology Inc. San Francisco, CA). Other antibodies used were rabbit anti-LMTK2 (Sigma-Aldrich) and anti-LMTK2 kinase domain (Cocalico Biologicals Inc., Reamstown, PA), mouse anti-Na,K-ATPase (Millipore), anti-FLAG M2 (Sigma-Aldrich), and anti-ezrin (BD Biosciences, San Jose, CA), and horseradish peroxide-conjugated goat anti-mouse, goat anti-rabbit, secondary antibodies (Bio-Rad). All antibodies were used at the concentrations recommended by the manufacturer. The following reagents were used: Complete Protease Inhibitor Mixture and PhosSTOP phosphatase inhibitor mixture tablets (Roche Applied Sciences, Indianapolis, IN), the adenylate cyclase activator forskolin and the cAMP phosphodiesterase inhibitor IBMX (3-isobutyl-1-methylxanthine) (Sigma-Aldrich), and the inhibitor of protein serine/threonine phosphatases calyculin A (Cell Signaling Technology, Inc.; Danvers, MA).
Immunoprecipitation and Immunoblotting
Endogenous CFTR and LMTK2 were immunoprecipitated from Calu-3 or HBE cell lysates by methods described previously (10, 15, 27). Briefly, cultured cells were lysed in an immunoprecipitation (IP) buffer containing 150 mm NaCl, 50 mm Tris, pH 7.4, 1% IGEPAL (Sigma-Aldrich), 5 mm MgCl2, 5 mm EDTA, 1 mm EGTA, 30 mm NaF, 1 mm Na3VO4, and Complete Protease Inhibitor mixture (Roche Applied Sciences, Basel, Switzerland). After centrifugation at 14,000 × g for 15 min to pellet insoluble material, the soluble lysates were pre-cleared by incubation with protein G or protein A, as appropriate, conjugated to Sepharose beads (Pierce Chemical Co.) at 4 °C. The pre-cleared lysates were added to the protein G- or protein A-Sepharose beads antibody complexes. CFTR was immunoprecipitated by incubation with the mouse M3A7 antibody and LMTK2 was immunoprecipitated by incubation with the rabbit anti-LMTK2 kinase domain antibody. Non-immune mouse or rabbit IgGs (DAKO North America, Inc., Carpinteria, CA) were used as controls. After washing the protein G- or protein A-Sepharose beads antibody complexes with the IP buffer, immunoprecipitated proteins were eluted by incubation at 85 °C for 5 min in sample buffer (Bio-Rad) containing 100 mm DTT. Immunoprecipitated proteins were separated by SDS-PAGE using 7.5% gels (Bio-Rad) and analyzed by Western blotting. The immunoreactive bands were visualized with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer LAS, Inc., Boston, MA).
RNA-mediated Interference
Transfection of CFBE41o- cells with siRNA targeting human LMTK2 gene (siLMTK2; Hs_LMTK2_6 siRNA; Qiagen, Valencia, CA) or the siRNA negative control (siCTRL; AllStars, Qiagen) was conducted using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer's instructions as we previously described (9, 10). For determination of the steady-state plasma membrane abundance of CFTR or CFTR endocytosis, CFBE41o- cells (1.0 × 106) were plated on collagen-coated tissue culture plates and incubated with the optimized transfection mixture containing 10 nm siRNA at 37 °C. The transfection medium was removed after 24 h and cells were cultured on the tissue culture plates until confluent. Under these conditions cells reached confluence at 96 h, and experiments were conducted at 96 h. Silencing the target genes resulted in the corresponding protein depletion by ∼70%. We aimed at such level of silencing to avoid off-target effects that may occur with more dramatic gene silencing.
For short-circuit recordings in Ussing-type chambers CFBE41o- cells (1.0 × 106) were plated on tissue culture plates and incubated with the optimized transfection mixture containing 50 nm siRNA at 37 °C. After 24 h, cells were trypsinized and plated on collagen-coated Snapwell permeable supports and cultured for an additional 6 days to establish polarized monolayers (total 7 days in culture). All experiments were done under the same cell culture conditions to assure similar cellular polarization as well as protein expression and trafficking (10). LMTK2 knockdown under these conditions resulted in the corresponding protein depletion by ∼70%.
Transduction of CFBE41o- cells with shRNAmir targeting the human LMTK2 gene (shLMTK2; V3LHS_345908 or V3LHS_638705) or shRNAmir negative control (RHS4348) in the lentiviral vector pGIPZ with TURBO-GFP reporter (Open Biosystems, Hunstville, AL) was carried at MOI 0.25 according to manufacturer's instructions. Cells transduced with shRNA were selected with puromycin for 5 days, subcultured to collagen-coated Snapwell filters at 1.0 × 106 and cultured in air-liquid interface for 7–9 days to form polarized monolayers.
Plasmids and Transient Transfection
The WT-LMTK2Δ-FLAG plasmid was constructed by inserting part of the human LMTK2 sequence coding for the first 600 amino acid residues corresponding to the transmembrane and kinase domain with an engineered C-terminal FLAG into pcDNA3.1 vector (Invitrogen) as previously described (37). The human WT-CFTR was subcloned into pcDNA3.1 vector without a tag (WT-CFTR) (34). To construct the kinase-deficient KM-LMTK2Δ-FLAG fragment the WT-LMTK2Δ-FLAG cDNA was mutated to introduce the K168M substitution and to construct the phosphorylation-deficient CFTR-S737A mutant the WT-CFTR cDNA was mutated using the QuikChange™ II XL site-directed mutagenesis kit (Stratagene) and the KOD Hot Start Kit (Novagene, Darmstadt, Germany). Constructs were sequence verified by ABI PRISM dye terminator cycle sequencing (Applied Biosystems, Foster City, CA). Transfection of cells with plasmids was performed using FuGENE6 (Roche Diagnostics), according to the manufacturer's instructions. CFBE41o- cells transfected with plasmid DNA were seeded on collagen-coated tissue culture plates until confluent. Under these conditions cells reached confluence at 48 h, and experiments were conducted at 48 h.
LMTK2 Kinase Assays
Kinase assays were performed as described previously (36). Briefly, HEK293 cells were transfected with WT-LMTK2Δ-FLAG, KM-LMTK2Δ-FLAG or empty pcDNA3.1 vector, and 24 h later, cells were lysed in RIPA buffer without sodium deoxycholate (1% (v/v) Triton X-100, 0.1% (w/v) SDS, 50 mm Tris, pH 7.4, and 150 mm NaCl. LMTK2 was immunoprecipitated with the anti-FLAG M2 antibody (Sigma) and protein G-agarose beads. The beads-antibody-protein complexes were washed three times with RIPA buffer and once with 2× kinase buffer (100 mm Hepes, pH 7.4, 40 mm MgCl2, 20% glycerol, 0.02 mg/ml BSA, and 0.02% Brij 35). The kinase assay was performed by incubating the beads for 2 h at 30 °C in a total reaction volume of 50 μl containing 1× kinase buffer, 10 μm ATP, and 20 μm of a peptide corresponding to CFTR residues 733–741 (ERRLSLVPD). A control reaction was performed as above with the exclusion of cell lysates. Extent of phosphorylation was determined using the Kinase-Glo Luminescent Assay (Promega) that assesses the amount of ATP remaining after the reaction and normalized for the amount of ATP in the control reaction.
Biochemical Determination of the Plasma Membrane CFTR
The determination of plasma membrane CFTR was performed by domain selective plasma membrane biotinylation in epithelial cell monolayers cultured on permeable growth supports or tissue culture plates using cell membrane impermeable EZ-Link™ Sulfo-NHS-LC-Biotin (Pierce Chemical Co.), followed by cell lysis in buffer containing 25 mm HEPES, pH 8.0, 1% Triton, 10% glycerol, and Complete Protease Inhibitor Mixture (Roche Applied Science), as described previously in detail (58, 59). Biotinylated CFTR was visualized by Western blotting using mouse monoclonal antibody clone 596 and an anti-mouse horseradish peroxidase antibody using the Western Lightning™ Plus-ECL detection system (Perkin Elmer Inc.; Waltham, MA) followed by chemiluminesence. Biotinylated FLAG-tagged LMTK2 fragments were visualized by Western blotting using mouse monoclonal anti-FLAG M2 antibody. Quantification of biotinylated CFTR or the FLAG-tagged LMTK2 was performed by densitometry using exposures within the linear dynamic range of the film. As previously demonstrated with appropriate intracellular controls, under cell culture conditions used in our study only the cell surface proteins are accessible to biotin at 4 °C (9). Western blotting for an intracellular protein, such as ezrin was used as a quality control during each experiment to confirm absence of intracellular proteins in the biotinylated protein samples. Only experiments in which ezrin was not detected in the biotinylated protein samples were included for analysis.
Endocytic Assays
Endocytic assays were performed in CFBE41o- cells, as described previously (10, 60). Briefly, the plasma membrane proteins were first biotinylated at 4 °C using cell membrane impermeable and cleavable EZ-Link™ Sulfo-NHS-SS-Biotin (Pierce Chemical Co.). Cells were rapidly warmed to 37 °C for different periods of time after biotinylation and, subsequently, the disulfide bonds on Sulfo-NHS-SS-biotinylated proteins remaining at the plasma membrane were reduced by l-glutathione (GSH; Sigma-Aldrich) at 4 °C. At this point in the protocol, biotinylated proteins reside within the endosomal compartment. Subsequently, cells were lysed, and biotinylated proteins were isolated by streptavidin-agarose beads, eluted into SDS-sample buffer, and separated by 7.5% SDS-PAGE. The amount of biotinylated CFTR at 4 °C and without the 37 °C warming was considered 100%. The amount of biotinylated CFTR remaining at the plasma membrane after GSH treatment at 4 °C and without the 37 °C warming was considered background (<7% compared with the amount of biotinylated CFTR at 4 °C without GSH treatment) and was subtracted from the CFTR biotinylated after warming to 37 °C at each time point. CFTR endocytosis was calculated after subtraction of the background and was expressed as the percent of biotinylated CFTR at each time point after warming to 37 °C compared with the amount of biotinylated CFTR present before warming to 37 °C. We have previously shown that the culture conditions and state of epithelial cell polarization affect CFTR endocytosis in human airway epithelial cells (9, 10, 26, 27). Because endocytic assays were performed in cells cultured on permeable supports or on plastic and in cells transfected with siRNA or plasmid DNA, we determined the time course of CFTR endocytosis for each cell culture and experimental condition and compared with appropriate controls.
Short-circuit Recordings
The short circuit currents (ISC) were measured in Ussing-type chambers (Physiological Instruments; San Diego, CA) as previously described (10, 61). In brief, monolayers of CFBE41o- cells grown on Snapwell permeable supports were mounted in an Ussing-type chamber (Physiologic Instruments) and bathed in solutions (see below) maintained at 37 °C and stirred by bubbling with 5% CO2/95% air. Short circuit current (Isc) was measured by voltage-clamping the transepithelial voltage across the monolayers to 0 mV with a voltage/current clamp (model VCC MC8, Physiologic Instruments). Transepithelial resistance was measured by periodically applying a 2.5-mV bipolar voltage pulse and was calculated using Ohm's law. The apical bath solution contained (in mm): 115 Na-gluconate, 5 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.8 K2HPO4, 1.2 MgCl2, 1.2 CaCl2, 10 mannitol (pH 7.4). The basolateral bath solution contained (in mm): 120 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.8 K2HPO4, 1.2 MgCl2, 1.2 CaCl2, 10.0 glucose (pH 7.4). A low Cl−, high-Na+, high-gluconate, apical bath solution was used to prevent cell swelling due to the increased apical Cl− permeability under these conditions, as previously described (10, 61). Following an equilibration period, the baseline ISC was recorded. Amiloride (10 μm) was added to the apical bath solution to inhibit Na+ absorption through ENaC. Subsequently, Isc was stimulated with forskolin (10 μm) and IBMX (50 μm) added to the apical and basolateral bath solutions followed by thiazolidonone CFTR inhibitor CFTRinh-172 (5 μm) added to the apical bath solution to inhibit CFTR-mediated Isc. Data are expressed as forskolin/IBMX stimulated Isc, calculated by subtracting the baseline Isc from the peak stimulated Isc.
Data Analysis and Statistics
Statistical analysis of the data were performed using GraphPad Prism version 4.0 for Macintosh (GraphPad Software Inc., San Diego, CA). The means were compared by a two-tailed t test. A p value <0.05 was considered significant. Data are expressed as mean ± S.E.
RESULTS
LMTK2 Localizes at the Plasma Membrane in Primary Differentiated Human Bronchial Epithelial Cells
Little is known about the distribution of LMTK2 in human airway epithelial cells. If LMTK2 affects CFTR, it would be expected that it localized, like CFTR, at the apical plasma membrane. Thus, we first examined localization of LMTK2 in primary differentiated HBE cells by domain-selective cell surface biotinylation and Western blotting (53). HBE cells were cultured for 6–8 weeks in air-liquid interface as polarized monolayers. LMTK2 was detected at both the apical and basolateral membrane domain (Fig. 1B). Next, we examined localization of LMTK2 in CFBE41o- cells, an immortalized human airway epithelial cell model because unlike HBE these cells are constantly available. Cells were cultured for 7–9 days in air-liquid interface as polarized monolayers. LMTK2 was detected at both the apical and basolateral membrane domain of similar to HBE cells (Fig. 1C).
Endogenous CFTR and LMTK2 Co-immunoprecipitate in Polarized Human Airway Epithelial Cells
We predicted that LMTK2 could interact with CFTR in polarized human airway epithelial cells. We used Calu-3 cells to study immunoprecipitation because these cells express both CFTR and LMTK2 endogenously, form polarized monolayers, and are constantly available as immortalized cells. Calu-3 cells were cultured for 3–4 weeks on semi-permeable growth supports as polarized monolayers. CFTR was immunoprecipitated with a monoclonal anti-CFTR antibody (M3A7), and LMTK2 was immunoprecipitated with a polyclonal anti-LMTK2 antibody. Western blot analysis demonstrated that endogenous CFTR and LMTK2 co-immunoprecipitate in a reciprocal fashion (Fig. 1, D and E). Taken together, the co-immunoprecipitation between endogenous CFTR and LMTK2 and their plasma membrane distribution in primary human airway epithelial cells suggest a physical association between CFTR and LMTK2 within the apical plasma membrane.
LMTK2 Knockdown Increases Plasma Membrane Abundance of CFTR in Human Airway Epithelial Cells
We hypothesized that LMTK2 controls CFTR trafficking at the plasma membrane in human airway epithelial cells. To test this hypothesis, LMTK2 expression was knocked down in CFBE41o- cells stably expressing WT-CFTR by RNA interference. We used CFBE41o- cells because these immortalized cell lines localize LMTK2 at the plasma membrane similar to the primary HBE cells as shown in Fig. 1. Moreover CFBE41o- cells serve as good models for CFTR trafficking (9, 10, 15, 61, 62). Cells were transfected with siRNA specific for the human LMTK2 sequence (siLMTK2) or with a siRNA control (siCTRL) and cultured on collagen-coated tissue culture plates for 96 h as monolayers (Fig. 2). The siLMTK2 reduced LMTK2 protein abundance in whole cell lysates by ∼70% without decreasing the levels of CFTR or ezrin (Fig. 2A). As determined by cell surface biotinylation and Western blotting, knockdown of LMTK2 increased the steady-state plasma membrane abundance of CFTR (Fig. 2, A and B).
LMTK2 Knockdown Increases the CFTR-mediated Isc Across Polarized Human Airway Epithelial Cells
CFTR mediated Cl− secretion is determined by the activity and number of CFTR Cl− channels at the plasma membrane. Because LMTK2 knockdown increased the plasma membrane abundance of CFTR, we analyzed the functionality of the rescued fraction, predicting that it would also increase CFTR-mediated Cl− secretion. siLMTK2 increased the forskolin/IBMX-stimulated Isc across CFBE41o- monolayers (Fig. 3). These results are consistent with the above data that siLMTK2 increased CFTR abundance at the plasma membrane and suggest that endogenous LMTK2 decreases CFTR-mediated Cl− secretion, at least in part by decreasing density of the CFTR Cl− channels at the plasma membrane in human airway epithelial cells.
LMTK2 Knockdown Decreases CFTR Endocytosis in Human Airway Epithelial Cells
Increased CFTR abundance at the plasma membrane could result from decreased endocytosis or increased recycling of CFTR. Endocytic assays were conducted to determine the mechanism of increased CFTR abundance at the plasma membrane due to LMTK2 knockdown. CFBE41o- cells stably expressing WT-CFTR were transfected with siRNA specific for human LMTK2 sequence (siLMTK2) or with a siRNA control (siCTRL) and cultured on collagen-coated tissue culture plates for 96 h as monolayers. Endocytic assays were performed by the GSH protection assay (10, 60). As illustrated in Fig. 4, siLMTK2 decreased CFTR endocytosis compared with siCTRL. Attenuation of CFTR endocytosis is consistent with increased steady-state plasma membrane abundance of CFTR in LMTK2 knockdown cells. Together, these data demonstrate that LMTK2 facilitates CFTR endocytosis in polarized human airway epithelial cells.
LMTK2 Phosphorylates CFTR in Human Airway Epithelial Cells
To determine whether CFTR is an LMTK2 substrate in airway epithelial cells, CFBE41o- cells stably expressing WT-CFTR and cultured as polarized monolayers on permeable growth supports for 7–9 days were treated with IBMX (1 mm) and forskolin (20 μm) added to the apical and basolateral medium at 37 °C for 10 min before experiments to raise the intracellular cAMP levels and promote PKA-mediated phosphorylation (34). To further enhance phosphorylation of CFTR we treated cells with the cell-permeable phosphatase inhibitor calyculin A (50 nm), added to the basolateral medium at 37 °C for 15 min before experiments (63, 64). Low levels of CFTR were detected by the phosphosite specific antibody Ab-737 in the vehicle control (CTRL)-treated cells, representing baseline levels of CFTR phosphorylated at Ser737 (CFTR-pS737; Fig. 5A). By contrast, CFTR phosphorylation was greatly enhanced after the forskolin/IBMX and calyculin A treatment (Fig. 5A). To demonstrate specificity of the phosphosite antibody, parental CFBE41o- cells were transiently transfected with WT-CFTR or CFTR with the S737A substitution (CFTR-S737A) inactivating the phosphorylation site (31). Even with calyculin A treatment of the cells, the CFTR-S737A mutant was not detected by antibody Ab-737, unlike the WT-CFTR (Fig. 5B). Together, these results demonstrate that the phosphosite antibody Ab-737 recognizes specifically the CFTR-pS737.
LMTK2 was shown to phosphorylate CFTR Ser737 in vitro (36). We assessed the effects of altering the LMTK2 kinase on CFTR phosphorylation in CFBE41o-. The residue Lys168 located upstream of the Walker A motif in the catalytic domain of LMTK2 is predicted to be critical for catalysis (49, 50). Site-directed mutagenesis was used to produce the K168M substitution in LMTK2 kinase domain. We expressed an LMTK2 fragment containing the first 600 amino acids including the transmembrane and kinase domain with an engineered C-terminal FLAG epitope tag (WT-LMTK2Δ-FLAG) and confirmed it was expressed at the plasma membrane, similar to endogenous LMTK2 (data not shown). Next, we expressed the K168M version (KM-LMTK2Δ-FLAG). Expressing the truncated LMTK2 fragments WT-LMTK2Δ-FLAG and KM-LMTK2Δ-FLAG in human airway epithelial cells eliminated the interactions mediated by the myosin VI binding domain and tail domain in the full-length LMTK2 and thus, allowed us to specifically examine effects mediated by the LMTK2 transmembrane and kinase domain.
To ascertain that the K168M mutation impairs LMTK2 kinase activity, we transfected HEK293 cells with the WT-LMTK2Δ-FLAG and KM-LMTK2Δ-FLAG or empty pcDNA3.1 vector and the resulting protein fragments were immunoprecipitated with anti-FLAG M2 antibody. The immunoprecipitated protein complexes were used to in vitro phosphorylate a peptide encompassing CFTR amino acids 733–741. Extent of phosphorylation was determined using the Kinase-Glo Luminescent Assay that assesses the amount of ATP remaining after the reaction normalized for the amount of ATP in the control reaction as described in “Materials and Methods.” ATP levels decreased in the reaction containing the WT-LMTK2Δ-FLAG indicating that LMTK2 phosphorylated the CFTR-derived peptide (Fig. 6, A and B). By contrast, ATP levels were similar in the reaction containing either the KM-LMTK2Δ-FLAG or vector control indicating that the K168M mutation impaired phosphorylation of the CFTR-derived peptide (Fig. 6, A and B). These results confirm the prediction that the residue Lys168 located in the catalytic domain of LMTK2 is critical for catalysis.
Next, we assessed phosphorylation of CFTR-Ser737 using the phosphosite antibody Ab-737. CFBE41o- cells stably expressing WT-CFTR were transfected with WT-LMTK2Δ-FLAG, KM-LMTK2Δ-FLAG, or vector control (V). Forty-eight hours after transfection cells were treated with calyculin A (50 nm) added to the basolateral medium at 37 °C for 15 min before experiments. CFTR-pS737 detected by immunoblotting with antibody Ab-737 was normalized for total CFTR detected with antibody CFF596. CFTR-pS737 abundance was decreased in cells expressing KM-LMTK2Δ-FLAG compared with WT-LMTK2Δ-FLAG or vector control (Fig. 6, C and D). Our conclusion was that the LMTK2 fragment with inactive kinase KM-LMTK2Δ-FLAG attenuated phosphorylation of CFTR-Ser737 because it competed with endogenous LMTK2 for phospohorylation of the CFTR-Ser737 site in CFBE41o- cells.
LMTK2-mediated Phosphorylation of CFTR Facilitates Endocytosis and Attenuates CFTR Abundance at Plasma Membrane
The above data have shown that LMTK2 facilitates CFTR endocytosis and that LMTK2 phosphorylates CFTR-Ser737 in human airway epithelial cells. Studies were conducted to determine whether CFTR endocytosis is regulated by the LMTK2 phosphorylation of CFTR-Ser737. Endocytic assays were performed to examine the effects of WT-LMTK2Δ-FLAG and KM-LMTK2Δ-FLAG on CFTR endocytosis. We determined the time course of CFTR endocytosis in CFBE41o- cells stably expressing WT-CFTR cultured for 48 h as monolayers on collagen-coated tissue culture plates. CFTR endocytosis reached maximum at 7.5 min (Fig. 7, A and B). Thus, in subsequent experiments we examined CFTR endocytosis at the 7.5-min time point. Differences in the magnitude and maximum of CFTR endocytosis in CFBE41o- cells cultured as polarized monolayers on permeable growth supports in Fig. 4 and CFBE41o- cells cultured as monolayers on tissue culture plates in Fig. 7 are consistent with the know effects of epithelial cell culture conditions on endocytic trafficking (65–67). CFBE41o- cells were transfected with the WT-LMTK2Δ-FLAG, KM-LMTK2Δ-FLAG, or vector control (V) and endocytic assays were performed 48 h after transfection when the cells formed monolayers. As expected from the effects on CFTR phosphorylation, the KM-LMTK2Δ-FLAG decreased CFTR endocytosis compared with either the WT-LMTK2Δ-FLAG or vector control (Fig. 7, C and D). Moreover, the KM-LMTK2Δ-FLAG increased the steady-state plasma membrane CFTR abundance when compared with the WT-LMTK2Δ-FLAG or vector control (Fig. 7, C and E). Inhibition of CFTR endocytosis is consistent with increased CFTR abundance at plasma membrane in the KM-LMTK2Δ-FLAG-transfected cells. Because expression of the WT-LMTK2Δ-FLAG did not increase phosphorylation of CFTR (Fig. 6, C and D) these conditions were not expected to alter endocytosis or the plasma membrane abundance of CFTR compared with vector control. Indeed, the WT-LMTK2Δ-FLAG had no effect on endocytosis or the plasma membrane abundance of CFTR compared with vector control (Fig. 7, C--E). Together, the above results demonstrate that the LMTK2 phosphorylation of CFTR-Ser737 facilitates CFTR endocytosis and reduces CFTR abundance at the plasma membrane.
Nothing is known about membrane trafficking of LMTK2 in human airway epithelial cells. Thus, to gain insight, we examined the plasma membrane abundance and endocytic uptake of the LMTK2 fragments in CFBE41o- cells. Approximately 70% of the WT-LMTK2Δ-FLAG was internalized in 7.5 min (Fig. 7, C and F). By contrast, internalization of the KM-LMTK2Δ-FLAG was decreased by 50%. Compared with the WT-LMTK2Δ-FLAG, the KM-LMTK2Δ-FLAG fragment was more abundant at the plasma membrane due to decreased endocytosis (Fig. 7, C and F). These data demonstrate for the first time the dynamic, kinase domain-dependent, spatial, and temporal regulation of LMTK2 distribution between the cell surface and endocytic compartments, consistent with the role of LMTK2 in endocytic trafficking in human airway epithelial cells.
The Phosphorylation-deficient CFTR-S737A Mutant is More Abundant at the Plasma Membrane Due to Decreased Endocytosis
If the LMTK2 mediated phosphorylation of CFTR-Ser737 induces CFTR endocytosis, eliminating the phosphorylation site by the S737A substitution should reduce CFTR endocytosis. Parental CFBE41o- cells were transfected with WT-CFTR or the CFTR-S737A mutant. We determined the time course of WT-CFTR endocytosis in parental CFBE41o- cells cultured for 48 h as monolayers on collagen-coated tissue culture plates. CFTR endocytosis reached maximum at 5 min (data not shown). Thus, in subsequent experiments we examined CFTR endocytosis at the 5-min time point. The S737A mutation attenuated CFTR endocytosis and increased the plasma membrane abundance of CFTR (Fig. 8). Together, the above results demonstrate that the LMTK2 phosphorylation of CFTR-Ser737 facilitates CFTR endocytosis and reduces the plasma membrane abundance of CFTR in human airway epithelial cells.
LMTK2 Knockdown Facilitates the Corrector-mediated Functional Rescue of ΔF508-CFTR
Although the small molecule VX-809 partially corrected the biosynthetic processing defect of ΔF508-CFTR in cultured cells, it had disappointing effects as a monotherapy in patients homozygous for the ΔF508 mutation (17, 21). Rescued ΔF508-CFTR demonstrates compromised plasma membrane stability due to altered post-maturational trafficking. Hence, correction of the trafficking defect may help to stabilize the mutant CFTR at the cell surface after the biosynthetic rescue (15, 20). Because LMTK2 knockdown increased the cell surface density of CFTR by inhibiting the endocytic uptake of CFTR, we examined whether this manipulation would facilitate the VX-809 mediated rescue of ΔF508-CFTR. CFBE41o- cells expressing ΔF508-CFTR were transduced with shRNA against LMTK2 (shLMTK2) or the shRNA negative control (shCTRL). Transduced cells were selected with puromycin. The concentration of puromycin was titrated to select cells transduced with a target copy number of viral particles producing LMTK2 knockdown without off-target effects (Fig. 9, A and B). VX-809 partially rescued the biosynthetic processing defect of ΔF508-CFTR demonstrated by appearance of the mature, fully glycosylated CFTR band C (Fig. 9C). Compared with control (shCTRL), LMTK2 knockdown increased band C abundance and the forskolin/IBMX-stimulated Isc across CFBE41o- monolayers (Figs. 9D and 10). These data indicate that LMTK2 knockdown facilitated the VX809-mediated rescue of ΔF508-CFTR.
DISCUSSION
The present study discovered that in human airway epithelial cells CFTR endocytosis is regulated by the LMTK2-mediated phosphorylation of CFTR-Ser737 that decreases the cell surface density of CFTR Cl− channels and inhibits CFTR-mediated Cl− secretion. The clinical implications of our findings are that regulating LMTK2 phosphorylation of CFTR may serve as a novel approach to stabilize CFTR at the cell surface. This approach may be particularly useful to stabilize pharmacologically rescued ΔF508-CFTR in CF patients.
Several lines of evidence support these conclusions. First, endogenous LMTK2 accumulated at the apical membrane domain of polarized human airway epithelial cells, including primary differentiated HBE cells and co-immunoprecipitated with CFTR, indicating that LMTK2 and CFTR physically associate within this membrane domain (Fig. 1). Second, inactivation by mutagenesis of the kinase activity in the truncated LMTK2 fragment KM-LMTK2Δ-FLAG inhibited phosphorylation of CFTR-Ser737 in human airway epithelial cells (Fig. 6). Compared with controls, LMTK2 knockdown or substitution by mutagenesis of the LMTK2 phosphorylation site in CFTR (CFTR-Ser737A) increased the steady-state plasma membrane abundance of CFTR and decreased its endocytosis (Figs. 2, 4, 8). Conversely, inactivation by mutagenesis of the LMTK2 kinase (KM-LMTK2Δ-FLAG) increased the steady-state plasma membrane abundance of CFTR and decreased CFTR endocytosis compared with the WT-LMTK2Δ-FLAG and endogenous LMTK2 (Fig. 7). Third, endogenous LMTK2 was sufficient to phosphorylate CFTR-Ser737 and facilitate CFTR endocytosis because when compared with vector control, expression of the LMTK2 fragment with intact kinase activity WT-LMTK2Δ-FLAG did not increase CFTR-Ser737 phosphorylation, or the steady-state plasma membrane abundance of CFTR and did not attenuate CFTR endocytosis (Figs. 6 and 7).
Studies have shown that LMTK2 interacts with multiple proteins, including myosin VI (reviewed in Ref. 48). We have previously demonstrated that myosin VI facilitates CFTR endocytosis (26); and others have shown that myosin VI and LMTK2 regulate endocytic trafficking in other cell model systems (42, 43). Using the truncated LMTK2 fragments without the myosin VI binding domain and the tail domain allowed us to demonstrate for the first time that the cell surface density and endocytosis of CFTR are regulated by phosphorylation mediated by the LMTK2 kinase. Future studies may determine how the protein-protein interactions mediated by other LMTK2 domains influence the cell surface density and endocytosis of CFTR.
The phosphorylation of CFTR-Ser737 by PKA and AMPK inhibits CFTR channel function (32, 33). We do not know whether LMTK2 phosphorylation of CFTR-Ser737 inhibit the CFTR channel function in addition to reducing the cell surface density of CFTR. Similarly, the effects of AMPK and PKA phosphorylation of CFTR-Ser737 on the cell surface CFTR abundance are unknown. Hence, it remains to be determined whether the phospho-dependent inhibitory effects on CFTR-Ser737 are differentially mediated by each of the three kinases. Our data indicate that LMTK2 plays physiologically relevant role in regulating the phospho-dependent inhibitory CFTR-Ser737 site in human airway epithelial cells because similar to mutagenesis of the Ser737 site, LMTK2 knockdown produced a 2-fold increase in the cell surface abundance of CFTR and a 3-fold decrease in CFTR endocytosis (Figs. 2B versus 8C and Figs. 4B versus 8B, respectively). When compared with the LMTK2 knockdown, the kinase deficient LMTK2 fragment produced lesser effect on the cell surface abundance and endocytosis of CFTR (Figs. 7E versus 2B and Figs. 7D versus 4B, respectively). Our interpretation is that endogenous LMTK2 diminished the effects of the kinase deficient fragment when compared with LMTK2 knockdown. Increased AMPK activity was proposed to facilitate phosphorylation of Ser737 and inhibition of CFTR in non-stimulated epithelia (34, 35). Similarly, increased activity of LMTK2 at the apical surface is expected to inhibit CFTR-mediated Cl− secretion at least in part by attenuating the cell surface density of CFTR. The LMTK2 gene polymorphisms and the protein kinase cdk5/p35 modulate LMTK2 function (68, 69); although, their effects on CFTR are unknown. By contrast, cigarette smoke exposure and chronic obstructive pulmonary diseases (COPD) reduce CFTR function by poorly defined mechanisms (reviewed in Ref. 70). Interestingly, cigarette smoke inhalation modifies the LMTK2 gene (69). Thus, examining effects of cigarette smoke exposure on LMTK2 may increase our understanding how this environmental toxin reduces CFTR function.
LMTK2 knockdown increased CFTR mediated Cl− secretion in cells expressing WT-CFTR and ΔF508-CFTR (Figs. 3 and 10). In cells expressing ΔF508-CFTR this effect was mediated by stabilizing the mature, fully glycosylated, plasma membrane associated CFTR band C rescued by corrector VX-809 (Figs. 9 and 10). The effect of VX-809 was small but similar to effects observed in previous studies (17, 61, 71). We observed an interesting correlation between the effects of LMTK2 knockdown on the biochemical and functional rescue where a 10% increase of the band C abundance translated into a 50% rise of the forskolin/IBMX-stimulated Isc (Figs. 9 and 10). Clinical studies have already shown that targeted monotherapy by the CFTR corrector in patients homozygous for the ΔF508 mutation is promising but still inadequate likely because of decreased function and reduced plasma membrane stability of the pharmacologically rescued ΔF508-CFTR (16, 17, 21, 72). Hence, regulating LMTK2 phosphorylation of ΔF508-CFTR may play a role together with the CFTR corrector and potentiator to maximally rescue ΔF508-CFTR function in CF patients. LMTK2 knockdown did not increase the steady-state abundance of the partially glycosylated ΔF508-CFTR band B and it did not rescue ΔF508-CFTR in the absence of VX-809 (Fig. 9C). These data emphasize that the effects of LMTK2 knockdown on CFTR were mediated via alterations of post-maturational trafficking of CFTR during endocytic uptake and not during the biosynthetic processing of CFTR.
Using the primary differentiated human bronchial epithelial cells and a human polarized airway epithelial cell model CFBE41o- we have shown that LMTK2 targets to the apical and basolateral plasma membrane. Moreover, we provide novel information that the kinase domain dynamically regulated the endocytic uptake of LMTK2 in human airway epithelial cells (Fig. 7, C and F).
In summary our data provide direct evidence that CFTR endocytosis is regulated by phosphorylation mediated by the LMTK2 kinase domain. Because rescued ΔF508-CFTR has decreased plasma membrane stability we propose that targeting LMTK2 phosphorylation of CFTR may offer a novel approach to investigate the stability defect and to design pharmacological approaches to stabilize rescued ΔF508-CFTR. Our findings may also point to a new direction in elucidating the mechanisms of decreased CFTR function in lung diseases resulting from cigarette smoke inhalation.
Acknowledgments
We thank Dr. John Wakefield from Tranzyme, Inc. (Birmingham, AL) who generated the CFBE41o- cells and Dr. J. P. Clancy from Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH who provided the cells. We thank Dr. Joseph Pilewski from the Cystic Fibrosis Research Center Epithelial Cell Core at the University of Pittsburg School of Medicine, Pittsburgh, PA for providing HBE cells and Stefanie Brown from the Epithelial Cell Core for technical assistance with HBE cell. We thank Dr. Raymond Frizzell from the Department of Cell Biology, University of Pittsburgh School of Medicine for a critical review of the manuscript.
This study was supported by National Institutes of Health Grants R01HL090767, R01HL090767-02S1, the Cystic Fibrosis Foundation SWIATE14P0, and the University of Pittsburgh Bridge Founding (to A. S-U.), the National Institutes of Health Grant P30DK072506 (to J. M. P., Cystic Fibrosis Research Center Epithelial Cell Core at the University of Pittsburgh School of Medicine, Pittsburgh, PA), the Portuguese FCT grants PEst-OE/BIA/UI4046/2011, MCTES PTDC/BIA-BCM/112635/2009, EXPL/BIM-MEC/1451/2013, and Romain Pauwels Research Award (to C. M. F.), and the Fellowship Grant SFRH/BD/47445/2008 (to S. L.).
- CFTR
- cystic fibrosis transmembrane conductance regulator
- ABC
- ATP binding cassette
- AMPK
- adenosine monophosphate-stimulated kinase
- LMTK
- lemur tyrosine kinase
- HBE
- human bronchial epithelial.
REFERENCES
- 1. Riordan J. R., Rommens J. M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J. L. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1173 [DOI] [PubMed] [Google Scholar]
- 2. Rommens J. M., Iannuzzi M. C., Kerem B., Drumm M. L., Melmer G., Dean M., Rozmahel R., Cole J. L., Kennedy D., Hidaka N. (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059–1065 [DOI] [PubMed] [Google Scholar]
- 3. Howard M., Jiang X., Stolz D. B., Hill W. G., Johnson J. A., Watkins S. C., Frizzell R. A., Bruton C. M., Robbins P. D., Weisz O. A. (2000) Forskolin-induced apical membrane insertion of virally expressed, epitope-tagged CFTR in polarized MDCK cells. Am. J. Physiol. Cell Physiol. 279, C375–C382 [DOI] [PubMed] [Google Scholar]
- 4. Boucher R. C. (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Resp. J. 23, 146–158 [DOI] [PubMed] [Google Scholar]
- 5. Tarran R., Button B., Boucher R. C. (2006) Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu. Rev. Physiol. 68, 543–561 [DOI] [PubMed] [Google Scholar]
- 6. Bertrand C. A., Frizzell R. A. (2003) The role of regulated CFTR trafficking in epithelial secretion. Am. J. Physiol. Cell Physiol. 285, C1–18 [DOI] [PubMed] [Google Scholar]
- 7. Guggino W. B., Stanton B. A. (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat. Rev. 7, 426–436 [DOI] [PubMed] [Google Scholar]
- 8. Cushing P. R., Vouilleme L., Pellegrini M., Boisguerin P., Madden D. R. (2010) A stabilizing influence: CAL PDZ inhibition extends the half-life of ΔF508-CFTR. Angewandte Chemie 49, 9907–9911 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ye S., Cihil K., Stolz D. B., Pilewski J. M., Stanton B. A., Swiatecka-Urban A. (2010) c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells. J. Biol. Chem. 285, 27008–27018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Cihil K. M., Ellinger P., Fellows A., Stolz D. B., Madden D. R., Swiatecka-Urban A. (2012) Disabled-2 protein facilitates assembly polypeptide-2-independent recruitment of cystic fibrosis transmembrane conductance regulator to endocytic vesicles in polarized human airway epithelial cells. J. Biol. Chem. 287, 15087–15099 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Riordan J. R. (2008) CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701–726 [DOI] [PubMed] [Google Scholar]
- 12. Lukacs G. L., Segal G., Kartner N., Grinstein S., Zhang F. (1997) Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation. Biochem. J. 328, 353–361 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Prince L. S., Peter K., Hatton S. R., Zaliauskiene L., Cotlin L. F., Clancy J. P., Marchase R. B., Collawn J. F. (1999) Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal. J. Biol. Chem. 274, 3602–3609 [DOI] [PubMed] [Google Scholar]
- 14. Sharma M., Benharouga M., Hu W., Lukacs G. L. (2001) Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J. Biol. Chem. 276, 8942–8950 [DOI] [PubMed] [Google Scholar]
- 15. Swiatecka-Urban A., Brown A., Moreau-Marquis S., Renuka J., Coutermarsh B., Barnaby R., Karlson K. H., Flotte T. R., Fukuda M., Langford G. M., Stanton B. A. (2005) The short apical membrane half-life of rescued uF508-CFTR results from accelerated endocytosis uF508-CFTR in polarized human airway epithelial cells. J. Biol. Chem. 280, 36762–36772 [DOI] [PubMed] [Google Scholar]
- 16. Molinski S., Eckford P. D., Pasyk S., Ahmadi S., Chin S., Bear C. E. (2012) Functional Rescue of F508del-CFTR Using Small Molecule Correctors. Front. Pharmacol. 3, 160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Van Goor F., Hadida S., Grootenhuis P. D., Burton B., Stack J. H., Straley K. S., Decker C. J., Miller M., McCartney J., Olson E. R., Wine J. J., Frizzell R. A., Ashlock M., Negulescu P. A. (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U. S.A. 108, 18843–18848 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Rogan M. P., Stoltz D. A., Hornick D. B. (2011) Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 139, 1480–1490 [DOI] [PubMed] [Google Scholar]
- 19. Lubamba B., Dhooghe B., Noel S., Leal T. (2012) Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. Clin. Biochem. 45, 1132–1144 [DOI] [PubMed] [Google Scholar]
- 20. Sharma M., Pampinella F., Nemes C., Benharouga M., So J., Du K., Bache K. G., Papsin B., Zerangue N., Stenmark H., Lukacs G. L. (2004) Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J. Cell Biol. 164, 923–933 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Clancy J. P., Rowe S. M., Accurso F. J., Aitken M. L., Amin R. S., Ashlock M. A., Ballmann M., Boyle M. P., Bronsveld I., Campbell P. W., De Boeck K., Donaldson S. H., Dorkin H. L., Dunitz J. M., Durie P. R., Jain M., Leonard A., McCoy K. S., Moss R. B., Pilewski J. M., Rosenbluth D. B., Rubenstein R. C., Schechter M. S., Botfield M., Ordoñez C. L., Spencer-Green G. T., Vernillet L., Wisseh S., Yen K., Konstan M. W. (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12–18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Peter K., Varga K., Bebok Z., McNicholas-Bevensee C. M., Schwiebert L., Sorscher E. J., Schwiebert E. M., Collawn J. F. (2002) Ablation of internalization signals in the carboxyl-terminal tail of the cystic fibrosis transmembrane conductance regulator enhances cell surface expression. J. Biol. Chem. 277, 49952–49957 [DOI] [PubMed] [Google Scholar]
- 23. Guggino W. B., Banks-Schlegel S. P. (2004) Macromolecular interactions and ion transport in cystic fibrosis. Am. J. Resp. Crit. Care Med. 170, 815–820 [DOI] [PubMed] [Google Scholar]
- 24. Collaco A., Jakab R., Hegan P., Mooseker M., Ameen N. (2010) α-AP-2 directs myosin VI-dependent endocytosis of cystic fibrosis transmembrane conductance regulator chloride channels in the intestine. J. Biol. Chem. 285, 17177–17187 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Fu L., Rab A., Tang L. P., Rowe S. M., Bebok Z., Collawn J. F. (2012) Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator. Biochem. J. 441, 633–643 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Swiatecka-Urban A., Boyd C., Coutermarsh B., Karlson K. H., Barnaby R., Aschenbrenner L., Langford G. M., Hasson T., Stanton B. A. (2004) Myosin VI Regulates Endocytosis of the Cystic Fibrosis Transmembrane Conductance Regulator. J. Biol. Chem. 279, 38025–38031 [DOI] [PubMed] [Google Scholar]
- 27. Swiatecka-Urban A., Talebian L., Kanno E., Moreau-Marquis S., Coutermarsh B., Hansen K., Karlson K. H., Barnaby R., Cheney R. E., Langford G. M., Fukuda M., Stanton B. A. (2007) Myosin Vb is required for trafficking of the cystic fibrosis transmembrane conductance regulator in Rab11a-specific apical recycling endosomes in polarized human airway epithelial cells. J. Biol. Chem. 282, 23725–23736 [DOI] [PubMed] [Google Scholar]
- 28. Luz S., Kongsuphol P., Mendes A. I., Romeiras F., Sousa M., Schreiber R., Matos P., Jordan P., Mehta A., Amaral M. D., Kunzelmann K., Farinha C. M. (2011) Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity. Mol. Cell. Biol. 31, 4392–4404 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Mendes A. I., Matos P., Moniz S., Luz S., Amaral M. D., Farinha C. M., Jordan P. (2011) Antagonistic regulation of cystic fibrosis transmembrane conductance regulator cell surface expression by protein kinases WNK4 and spleen tyrosine kinase. Mol. Cell. Biol. 31, 4076–4086 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Moniz S., Sousa M., Moraes B. J., Mendes A. I., Palma M., Barreto C., Fragata J. I., Amaral M. D., Matos P. (2013) HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem. Biol. 8, 432–442 [DOI] [PubMed] [Google Scholar]
- 31. Alzamora R., King J. D., Jr., Hallows K. R. (2011) CFTR regulation by phosphorylation. Methods Mol. Biol. 741, 471–488 [DOI] [PubMed] [Google Scholar]
- 32. Wilkinson D. J., Strong T. V., Mansoura M. K., Wood D. L., Smith S. S., Collins F. S., Dawson D. C. (1997) CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain. The Am. J. Physiol. 273, L127–L133 [DOI] [PubMed] [Google Scholar]
- 33. Hegedus T., Aleksandrov A., Mengos A., Cui L., Jensen T. J., Riordan J. R. (2009) Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A. Biochim. Biophys. Acta 1788, 1341–1349 [DOI] [PubMed] [Google Scholar]
- 34. Kongsuphol P., Cassidy D., Hieke B., Treharne K. J., Schreiber R., Mehta A., Kunzelmann K. (2009) Mechanistic insight into control of CFTR by AMPK. J. Biol. Chem. 284, 5645–5653 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Kongsuphol P., Hieke B., Ousingsawat J., Almaca J., Viollet B., Schreiber R., Kunzelmann K. (2009) Regulation of Cl(-) secretion by AMPK in vivo. Pflugers Arch 457, 1071–1078 [DOI] [PubMed] [Google Scholar]
- 36. Wang H., Brautigan D. L. (2006) Peptide microarray analysis of substrate specificity of the transmembrane Ser/Thr kinase KPI-2 reveals reactivity with cystic fibrosis transmembrane conductance regulator and phosphorylase. Mol. Cell Proteomics 5, 2124–2130 [DOI] [PubMed] [Google Scholar]
- 37. Wang H., Brautigan D. L. (2002) A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2. J. Biol. Chem. 277, 49605–49612 [DOI] [PubMed] [Google Scholar]
- 38. Kesavapany S., Lau K. F., Ackerley S., Banner S. J., Shemilt S. J., Cooper J. D., Leigh P. N., Shaw C. E., McLoughlin D. M., Miller C. C. (2003) Identification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinase. J. Neurosci. 23, 4975–4983 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Kawa S., Fujimoto J., Tezuka T., Nakazawa T., Yamamoto T. (2004) Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling. Genes Cells 9, 219–232 [DOI] [PubMed] [Google Scholar]
- 40. Tomomura M., Morita N., Yoshikawa F., Konishi A., Akiyama H., Furuichi T., Kamiguchi H. (2007) Structural and functional analysis of the apoptosis-associated tyrosine kinase (AATYK) family. Neuroscience 148, 510–521 [DOI] [PubMed] [Google Scholar]
- 41. Nixon A., Jia Y., White C., Bradbury N. A. (2013) Determination of the membrane topology of lemur tyrosine kinase 2 (LMTK2) by fluorescence protease protection. Am. J. Physiol. Cell Physiol. 304, C164–C169 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Chibalina M. V., Seaman M. N., Miller C. C., Kendrick-Jones J., Buss F. (2007) Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment. J. Cell Sci. 120, 4278–4288 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Inoue T., Kon T., Ohkura R., Yamakawa H., Ohara O., Yokota J., Sutoh K. (2008) BREK/LMTK2 is a myosin VI-binding protein involved in endosomal membrane trafficking. Genes Cells 13, 483–495 [DOI] [PubMed] [Google Scholar]
- 44. Manser C., Guillot F., Vagnoni A., Davies J., Lau K. F., McLoughlin D. M., De Vos K. J., Miller C. C. (2012) Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene 31, 2773–2782 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Tsai L. H., Delalle I., Caviness V. S., Jr., Chae T., Harlow E. (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419–423 [DOI] [PubMed] [Google Scholar]
- 46. Lew J., Huang Q. Q., Qi Z., Winkfein R. J., Aebersold R., Hunt T., Wang J. H. (1994) A brain-specific activator of cyclin-dependent kinase 5. Nature 371, 423–426 [DOI] [PubMed] [Google Scholar]
- 47. Fu A. K., Fu W. Y., Cheung J., Tsim K. W., Ip F. C., Wang J. H., Ip N. Y. (2001) Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat. Neurosci. 4, 374–381 [DOI] [PubMed] [Google Scholar]
- 48. Rattray M. (2012) New insights on regulation of LMTK2, a membrane kinase integrating pathways central to neurodegeneration. J. Neurochem. 121, 327–328 [DOI] [PubMed] [Google Scholar]
- 49. Marchler-Bauer A., Anderson J. B., DeWeese-Scott C., Fedorova N. D., Geer L. Y., He S., Hurwitz D. I., Jackson J. D., Jacobs A. R., Lanczycki C. J., Liebert C. A., Liu C., Madej T., Marchler G. H., Mazumder R., Nikolskaya A. N., Panchenko A. R., Rao B. S., Shoemaker B. A., Simonyan V., Song J. S., Thiessen P. A., Vasudevan S., Wang Y., Yamashita R. A., Yin J. J., Bryant S. H. (2003) CDD: a curated Entrez database of conserved domain alignments. Nucleic Acids Res. 31, 383–387 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Marchler-Bauer A., Zheng C., Chitsaz F., Derbyshire M. K., Geer L. Y., Geer R. C., Gonzales N. R., Gwadz M., Hurwitz D. I., Lanczycki C. J., Lu F., Lu S., Marchler G. H., Song J. S., Thanki N., Yamashita R. A., Zhang D., Bryant S. H. (2013) CDD: conserved domains and protein three-dimensional structure. Nucleic Acids Res. 41, D348–D352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Devor D. C., Bridges R. J., Pilewski J. M. (2000) Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am. J. Physiol. Cell Physiol. 279, C461–C479 [DOI] [PubMed] [Google Scholar]
- 52. Myerburg M. M., Latoche J. D., McKenna E. E., Stabile L. P., Siegfried J. S., Feghali-Bostwick C. A., Pilewski J. M. (2007) Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1352–L1360 [DOI] [PubMed] [Google Scholar]
- 53. Snodgrass S. M., Cihil K. M., Cornuet P. K., Myerburg M. M., Swiatecka-Urban A. (2013) Tgf-β1 Inhibits Cftr Biogenesis and Prevents Functional Rescue of DeltaF508-Cftr in Primary Differentiated Human Bronchial Epithelial Cells. PloS one 8, e63167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Neuberger T., Burton B., Clark H., Van Goor F. (2011) Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods Mol. Biol. 741, 39–54 [DOI] [PubMed] [Google Scholar]
- 55. Hentchel-Franks K., Lozano D., Eubanks-Tarn V., Cobb B., Fan L., Oster R., Sorscher E., Clancy J. P. (2004) Activation of airway cl- secretion in human subjects by adenosine. Am. J. Resp. Cell Mol. Biol. 31, 140–146 [DOI] [PubMed] [Google Scholar]
- 56. Chang C., Wang X., Caldwell R. B. (1997) Serum opens tight junctions and reduces ZO-1 protein in retinal epithelial cells. J. Neurochem. 69, 859–867 [DOI] [PubMed] [Google Scholar]
- 57. Kues W. A., Anger M., Carnwath J. W., Paul D., Motlik J., Niemann H. (2000) Cell cycle synchronization of porcine fetal fibroblasts: effects of serum deprivation and reversible cell cycle inhibitors. Biol. Reprod. 62, 412–419 [DOI] [PubMed] [Google Scholar]
- 58. Moyer B. D., Loffing J., Schwiebert E. M., Loffing-Cueni D., Halpin P. A., Karlson K. H., Ismailov I. I., Guggino W. B., Langford G. M., Stanton B. A. (1998) Membrane trafficking of the cystic fibrosis gene product, cystic fibrosis transmembrane conductance regulator, tagged with green fluorescent protein in madin-darby canine kidney cells. J. Biol. Chem. 273, 21759–22168 [DOI] [PubMed] [Google Scholar]
- 59. Swiatecka-Urban A., Duhaime M., Coutermarsh B., Karlson K. H., Collawn J., Milewski M., Cutting G. R., Guggino W. B., Langford G., Stanton B. A. (2002) PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 277, 40099–40105 [DOI] [PubMed] [Google Scholar]
- 60. Cihil K. M., Swiatecka-Urban A. (2013) The Cell-based L-Glutathione Protection Assays to Study Endocytosis and Recycling of Plasma Membrane Proteins. J. Vis. Exp. 82, e50867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Cihil K. M., Zimnik A., Swiatecka-Urban A. (2013) c-Cbl reduces stability of rescued F508-CFTR in human airway epithelial cells: Implications for cystic fibrosis treatment. Commun. Integr. Biol. 6, e23094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Madden D. R., Swiatecka-Urban A. (2012) Tissue-specific control of CFTR endocytosis by Dab2: Cargo recruitment as a therapeutic target. Commun. Integr. Biol. 5, 473–476 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Ishihara H., Martin B. L., Brautigan D. L., Karaki H., Ozaki H., Kato Y., Fusetani N., Watabe S., Hashimoto K., Uemura D. (1989) Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 159, 871–877 [DOI] [PubMed] [Google Scholar]
- 64. Holy M., Brautigan D. L. (2012) Calyculin A from Discodermia calyx is a dual action toxin that blocks calcium influx and inhibits protein Ser/Thr phosphatases. Toxins 4, 940–954 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Mukherjee S., Ghosh R. N., Maxfield F. R. (1997) Endocyt. Physiol. Rev. 77, 759–803 [DOI] [PubMed] [Google Scholar]
- 66. Roush D. L., Gottardi C. J., Naim H. Y., Roth M. G., Caplan M. J. (1998) Tyrosine-based membrane protein sorting signals are differentially interpreted by polarized Madin-Darby canine kidney and LLC-PK1 epithelial cells. J. Biol. Chem. 273, 26862–26869 [DOI] [PubMed] [Google Scholar]
- 67. Mostov K. E., Verges M., Altschuler Y. (2000) Membrane traffic in polarized epithelial cells. Curr. Opin. Cell Biol. 12, 483–490 [DOI] [PubMed] [Google Scholar]
- 68. Harries L. W., Perry J. R., McCullagh P., Crundwell M. (2010) Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 10, 315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Seo J. S., Ju Y. S., Lee W. C., Shin J. Y., Lee J. K., Bleazard T., Lee J., Jung Y. J., Kim J. O., Yu S. B., Kim J., Lee E. R., Kang C. H., Park I. K., Rhee H., Lee S. H., Kim J. I., Kang J. H., Kim Y. T. (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109–2119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Rab A., Rowe S. M., Raju S. V., Bebok Z., Matalon S., Collawn J. F. (2013) Cigarette Smoke and CFTR: Implications in the pathogenesis of COPD. Am. J. Physiol. Lung Cell Mol. Physiol. 305, L530–L541 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71. Holleran J. P., Glover M. L., Peters K. W., Bertrand C. A., Watkins S. C., Jarvik J. W., Frizzell R. A. (2012) Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol. Med. 18, 685–696 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Van Goor F., Yu H., Burton B., Hoffman B. J. (2014) Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13, 29–36 [DOI] [PubMed] [Google Scholar]